Shanghai Cell Therapy Group has secured nearly 500 million yuan ($76.6 million) in a Series D1 round of financing to advance its R&D, talent recruitment, and clinical trials of product candidates.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
